Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants

A Randomized, Double-blind, Placebo/Positive Control, Dose-finding Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of SIBP-A16 Injection in Premature Infants and Full-term Infants

This trial employs a randomized, double-blind, placebo/positive control, and dose-finding design to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of SIBP-A16 injection in premature and term infants.

Study Overview

• Status: Not yet recruiting
• Conditions: Respiratory Syncytial Virus (RSV)
• Intervention / Treatment: Drug: SIBP-A16 injection; Drug: Nirsevimab; Drug: SIBP-A16 buffer solution

Detailed Description

This study established three study groups: the test drug group, the placebo group, and the positive control group. Four dose cohorts were set up: Cohort 1 (Dose 1), Cohort 2 (Dose 2), Cohort 3 (Dose 3), and Cohort 4 (Dose 2). A total of 36 participants were enrolled. The drug will be administered via intramuscular injection as a single dose. Initially, Cohort 1 enrolled 7 participants, who were randomly assigned to receive either one dose of the test drug or placebo. After completing the initial 14-day safety observation, if the dose escalation termination criteria were not triggered, participants were enrolled into Cohort 2 (11 participants, randomly assigned to receive either one dose of the test drug or placebo). Once Cohort 2 was fully enrolled, participants could be enrolled into Cohort 4 (7 participants, randomly assigned to receive either one dose of the positive control drug or placebo). After Cohort 2 completed the 14-day safety observation, participants were enrolled into Cohort 3 (11 participants, randomly assigned to receive either one dose of the test drug or placebo) following the same procedure. If the dose escalation termination criteria were triggered, the Data Monitoring Committee (DMC) would conduct a safety assessment and discuss with the research team and sponsor whether to terminate the dose escalation.

• Study Type: Interventional
• Enrollment (Estimated): 36
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Dandan Chen, Master; Phone Number: 86-021-62800991; Email: ddchen.sh@sinopharm.com
• Study Contact Backup: Name: Bin Wu, Bachelor; Phone Number: 02162800991; Email: wubin50@sinopharm.com

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China
      • West China Second Hospital, Sichuan University
      • Contact: Hanwen Liu; Phone Number: 86-18980602109; Email: hanmin@vip.163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• During screening, infants within 1 year of age, including premature infants (gestational age ≥29 to <35 weeks) and full-term infants (gestational age ≥35 weeks), with underlying diseases but no other risk factors, are allowed to participate in the trial;
• Infants with a body weight ≥3 kg at screening;
• Infants who are entering their first RSV infection season at screening;
• Parents/legal guardians of trial participants have signed the informed consent form;
• Parents/legal guardians of trial participants are able to understand and comply with the requirements and procedures of the protocol, including scheduled center visits, telephone interviews, and blood sample collection;
• Participants can complete the follow-up period, which is approximately 1 year after the administration of the study drug.

Exclusion Criteria:

• Any fever (≥37.5°C, axillary temperature) or acute illness (defined as the presence of moderate or severe symptoms or signs) occurring within 7 days prior to drug administration;
• Having experienced Lower Respiratory Tract Infections (LRTI) within the previous 7 days prior to randomization, or having active LRTI at the time of randomization;
• Individuals with chronic eczema or urticaria, or those with an allergic constitution who are allergic to multiple drugs, or those with a known history of allergy to immunoglobulin products, blood products, other exogenous proteins, or any components of this product;
• Had a history of RSV infection before randomization, or had active RSV infection at the time of randomization;
• Those who have received non-oral inactivated vaccines or component vaccines within 7 days before administration;
• Having received a non-oral live attenuated vaccine within 30 days prior to drug administration;
• Participants who have received any medication within 7 days prior to drug administration, except for: a) various vitamins and iron supplements; b) systemic over-the-counter medications (such as analgesics) for common pediatric symptoms, which may be used occasionally, as determined by the investigator;
• Participants with autoimmune diseases who are currently receiving, or are expected to receive according to the investigator's judgment, immunosuppressive therapy (including steroids, excluding topical steroids) during the trial period;
• Have previously used or are expected to receive blood products or immunoglobulin products during the trial period;
• Known renal dysfunction or liver dysfunction;
• Known to have chronic lung disease (CLD)/bronchopulmonary dysplasia;
• Congenital respiratory abnormalities with clinical significance;
• Suffering from congenital heart disease (CHD) accompanied by significant hemodynamic changes;
• Suffering from chronic epilepsy or progressive or unstable neurological disorders;
• Those who have previously experienced or are suspected to have experienced life-threatening acute events, and are still deemed unsuitable for participating in clinical trials by the researchers;
• Known immune deficiency, including infection with human immunodeficiency virus (HIV);
• The mother is infected with HIV (unless it has been proven that the trial participant is not infected);
• The mother received the RSV vaccine during pregnancy;
• Have received any investigational drugs or participated in any intervention studies;
• Any other circumstances that the researcher believes may interfere with the evaluation of the study drug or the interpretation of the study results;
• The participants are the children of the researchers, their subordinate researchers, relatives, or staff members of the sponsor.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; SIBP-A16 injection	Drug: SIBP-A16 injection; Strength: dose 1, dose 2 and dose 3. Single administration via intramuscular or intravenous injection.
Active Comparator: Positive Comparator; Nirsevimab	Drug: Nirsevimab; Participants will receive one dose of Nisibimab via intramuscular injection.
Placebo Comparator: Placebo; SIBP-A16 buffer solution	Drug: SIBP-A16 buffer solution; Participants in the placebo group will be assigned to four dose cohorts, and they will receive one dose of Placebo via intramuscular injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AE (Adverse Events)	That is adverse events, any adverse events that occurred to the participant during the study period.	From day 1 to day 360 after administration
SAE (Serious Adverse Events)	That is serious adverse events, any serious adverse events that occurred to the participant during the study period.	From day 1 to day 360 after administration
Adverse Event of Special Interest (AESI)	Adverse events defined in the protocol that require special attention, such as abnormal liver function, anaphylactic reaction, hypersensitivity reaction, etc.	From day 1 to day 360 after administration
New-onset chronic diseases (NOCD)	NOCD refer to chronic non-communicable diseases that emerge during clinical trials.	From day 1 to day 360 after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC (Area Under The Plasma Concentration Versus Time Curve)	It shows the degree to which a drug is absorbed and used in the body.	Before injection, on the 7th, 30th, 90th, 150th and 360th days after administration
Cmax (Peak Plasma Concentration)	It shows the highest plasma concentration of a drug that can be achieved after administration.	Before injection, on the 7th, 30th, 90th, 150th and 360th days after administration
Tmax (Peak Time)	That is peak time of drug action, it shows the time required to reach the maximum concentration on the participant plasma concentration curve after administration.	Before injection, on the 7th, 30th, 90th, 150th and 360th days after administration
Detecting RSV neutralizing antibody activity at various time points	The RSV neutralizing assay was used to analyze the neutralizing activity of participants against RSV at various time points (before administration, and on days 7, 30, 90, 150, and 360 after administration).	Before injection, on the 7th, 30th, 90th, 150th and 360th days after administration
Level of Anti-drug antibody (ADA)	If ADA is positive, further use validated analytical methods to detect the anti-SIBP-A16 neutralizing antibody (Nab).	Before injection, on the 30th, 150th and 360th days after administration

Collaborators and Investigators

• Sponsor: Shanghai Institute Of Biological Products
• Investigators: Principal Investigator: Hanwen Liu, West China Second Hospital, Sichuan University

Study record dates

Study Major Dates

• Study Start (Estimated): January 15, 2026
• Primary Completion (Estimated): March 31, 2027
• Study Completion (Estimated): March 31, 2027

Study Registration Dates

• First Submitted: January 5, 2026
• First Submitted That Met QC Criteria: January 14, 2026
• First Posted (Actual): January 23, 2026

Study Record Updates

• Last Update Posted (Actual): January 23, 2026
• Last Update Submitted That Met QC Criteria: January 14, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Safety; Pharmacokinetics; RSV; Tolerability; Preliminary efficacy; Premature and term infants
• Additional Relevant MeSH Terms: Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Obstetric Labor, Premature; Obstetric Labor Complications; Pregnancy Complications; Premature Birth; nirsevimab
• Other Study ID Numbers: SIBP-A16-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No